glp-1 cv outcome trials receptor agonists were developed for glycemic control. The cardiovascular data has since reframed how cardiologists need to think about this drug class entirely. Across LEADER, SUSTAIN-6, REWIND, and SELECT, GLP-1 Summary of large cardiovascular outcomes
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13



























